Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Announces Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) issued its earnings results on Tuesday. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19, FiscalAI reports. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $72.98 on Tuesday. Kiniksa Pharmaceuticals International has a 1-year low of $35.20 and a 1-year high of $84.06. The stock has a market cap of $5.69 billion, a PE ratio of 75.24 and a beta of 0.04. The firm has a 50-day simple moving average of $78.03 and a two-hundred day simple moving average of $59.00.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KNSA. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Canaccord Genuity Group upped their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Wells Fargo & Company initiated coverage on Kiniksa Pharmaceuticals International in a research report on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 price objective for the company. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Citigroup raised their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.14.

Insider Buying and Selling

In other news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares in the company, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 51.98% of the stock is currently owned by insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.